Grey Matters Health Inc. operates as a clinical stage pharmaceutical development company in Canada, the United States, and Australia. The company focuses on developing the therapeutic drugs in the areas of non-alcoholic steatohepatitis, liver disease, chronic kidney disease, and stroke program. Its pipeline includes repirinast for the treatment of chronic kidney disease; and N,N-Dimethyltryptamine for the treatment of strokes and traumatic brain injuries. The company was formerly known as Algernon Health Inc. and changed its name to Grey Matters Health Inc. in April 2026. Algernon Health Inc. was incorporated in 2015 and is headquartered in Vancouver, Canada.
Frequently asked questions
What sector does Algernon Pharmaceuticals Inc (AGNPF) operate in?
Algernon Pharmaceuticals Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Algernon Pharmaceuticals Inc (AGNPF) current stock price?
As of the latest data, Algernon Pharmaceuticals Inc stock price is $0.33, with a previous close of $0.32. Algernon Pharmaceuticals Inc gained $0.01 in the last trading session, representing a 1.95% increase.
What is Algernon Pharmaceuticals Inc (AGNPF) current market capitalization?
Algernon Pharmaceuticals Inc market cap is approximately 1.79 million.
What is Algernon Pharmaceuticals Inc (AGNPF) Earnings Per Share (EPS)?
The trailing EPS is -$0.37.
Does Algernon Pharmaceuticals Inc (AGNPF) pay dividends?
No. Algernon Pharmaceuticals Inc does not pay a dividend.
What is Algernon Pharmaceuticals Inc (AGNPF) beta (volatility) score?
Algernon Pharmaceuticals Inc has a beta of 0.906, meaning its volatility is roughly in line with the market.
